FDA-approved drug sensitises brain cancer cells to radiotherapy
Drug Discovery World
JANUARY 23, 2023
This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “Our GBM is a WHO grade IV brain tumour with dismal prognosis.
Let's personalize your content